Comparing Acute Pain Management Protocols for Patients With Sickle Cell Disease

PHASE4CompletedINTERVENTIONAL
Enrollment

106

Participants

Timeline

Start Date

March 15, 2015

Primary Completion Date

May 31, 2016

Study Completion Date

June 30, 2016

Conditions
Sickle Cell Disease
Interventions
DRUG

Hydromorphone (Standardized, weight-based dosing)

Standardized analgesic management using a SCD specific standard protocol based on NHBLI guidelines (initial opioid dose weight-based).

DRUG

Morphine Sulfate (Standardized, weight-based dosing)

Standardized analgesic management using a SCD specific standard protocol based on NHBLI guidelines (initial opioid dose weight-based).

DRUG

Hydromorphone (Patient Specific dosing)

Patient specific analgesic management, with specific opioid dosage and frequency based on a protocol developed by a patient's healthcare team.

DRUG

Morphine Sulfate (Patient Specific dosing)

Patient specific analgesic management, with specific opioid dosage and frequency based on a protocol developed by a patient's healthcare team.

Trial Locations (2)

10029

Mount Sinai Hospital, New York

45219

University of Cincinnati Medical Center, Cincinnati

Sponsors

Lead Sponsor

All Listed Sponsors
collaborator

National Institutes of Health (NIH)

NIH

collaborator

National Heart, Lung, and Blood Institute (NHLBI)

NIH

collaborator

University of Cincinnati

OTHER

collaborator

Mount Sinai Hospital, New York

OTHER

lead

Duke University

OTHER

NCT02222246 - Comparing Acute Pain Management Protocols for Patients With Sickle Cell Disease | Biotech Hunter | Biotech Hunter